Gallbladder Cancer Pipeline Analysis Report 2026

Report Coverage

The Gallbladder Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into gallbladder cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gallbladder cancer. The gallbladder cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The gallbladder cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with gallbladder cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to gallbladder cancer.

Read more about this report - Request a Free Sample

Gallbladder Cancer Pipeline Outlook

The gallbladder cancer pipeline outlook highlights growing efforts to address a disease with limited effective systemic options. Standard treatment typically involves surgical resection for early-stage disease, followed by chemotherapy regimens such as gemcitabine-based combinations in advanced settings, where outcomes remain poor. Pipeline development is increasingly focused on targeted and novel therapies to improve survival.

Gallbladder cancer treatment is witnessing renewed momentum as regulatory advancements support innovation within this underserved oncology space. In October 2025, the US FDA granted Orphan Drug Designation to MDX-124, a first-in-class therapeutic under evaluation for biliary tract cancers, including gallbladder cancer. Early Phase 1b data demonstrated encouraging tumor control and tolerability, supporting continued clinical development and reinforcing innovation within this underserved oncology pipeline.

Gallbladder Cancer Epidemiology

Gallbladder cancer is a relatively rare yet highly fatal malignancy, ranking 22nd in global cancer incidence with an estimated 122,491 new cases and 89,055 deaths worldwide in 2022 according to GLOBOCAN. Incidence and mortality rates vary significantly by region, with the highest cases reported in China, India, and Japan, and age-standardized rates elevated in parts of South America. The disease disproportionately affects adults aged 50–74, and mortality remains high due to late diagnosis and limited screening programs.

Gallbladder Cancer – Pipeline Therapeutic Assessment

Gallbladder Cancer Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total gallbladder cancer clinical trials. Phase II dominates with 60%, followed by phase III 24%, and phase I with 15%, highlighting mid-stage development focus. Overall, this distribution reflects a strong emphasis on mid-stage clinical validation, with a growing pipeline advancing toward late-stage development to address unmet therapeutic needs in gallbladder cancer.

Gallbladder Cancer Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the gallbladder cancer pipeline analysis include small molecules, monoclonal antibodies, peptides, and Polymers. The gallbladder cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gallbladder cancer. In November 2024,
the U.S. FDA granted accelerated approval to zanidatamab-hrii (Ziihera®) for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, which includes gallbladder cancer. This bispecific HER2-targeting antibody showed a ~52 % objective response rate in the HERIZON-BTC-01 trial, representing a significant advance where few targeted options existed. The approval also included a companion diagnostic to identify eligible patients.

Gallbladder Cancer Clinical Trials – Key Players

The EMR report for the gallbladder cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gallbladder cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gallbladder cancer clinical trials:

• AccSalus Biosciences, Inc.
• Tango Therapeutics, Inc.
• Bayer
• Arvinas Inc.
• Celgene
• Compass Therapeutics
• MedImmune
• Ohara Pharmaceutical

Gallbladder Cancer – Emerging Drugs Profile

Key Questions Answered in the Gallbladder Cancer Pipeline Insight Report

• Which companies/institutions are leading the gallbladder cancer drug development?
• Which company is leading the gallbladder cancer pipeline development activities?
• What is the current gallbladder cancer commercial assessment?
• What are the opportunities and challenges present in the gallbladder cancer pipeline landscape?
• What is the efficacy and safety profile of gallbladder cancer pipeline drugs?
• Which company is conducting major trials for gallbladder cancer drugs?
• Which companies/institutions are involved in gallbladder cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in gallbladder cancer?

Reasons To Buy This Report

The Gallbladder Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gallbladder cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gallbladder cancer collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Gallbladder Cancer Market

Gallbladder Cancer Epidemiology Forecast